Comparative Pharmacology
Head-to-head clinical analysis: GLUMETZA versus RIOMET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GLUMETZA versus RIOMET.
GLUMETZA vs RIOMET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metformin hydrochloride, a biguanide, improves glucose tolerance in type 2 diabetes mellitus by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity (increasing peripheral glucose uptake and utilization).
Biguanide that decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Initial: 500 mg orally once daily with evening meal; increase by 500 mg weekly based on tolerability. Maximum: 2000 mg once daily with evening meal. Extended-release formulation.
Oral, 500 mg twice daily or 850 mg once daily, increased gradually to 2000 mg daily in divided doses.
None Documented
None Documented
6.2 hours (terminal) in healthy adults; prolonged in renal impairment (e.g., 18 hours in CrCl <30 mL/min)
Terminal elimination half-life: 6.2 hours (range 4–12 hours); clinical context: 4–5 half-lives to steady state (approx 24–36 hours); prolonged in renal impairment (e.g., creatinine clearance <60 mL/min contraindicated)
Renal (90% as unchanged drug); fecal (minor, <5%)
Renal (90% unchanged via glomerular filtration and tubular secretion); fecal (10%)
Category C
Category C
Biguanide Antidiabetic
Biguanide Antidiabetic